A tailored <i>in vivo</i> CRISPR screen identifies <i>BAP1</i> as a potent tumor suppressor of soft tissue sarcoma
Jianguo Huang(Duke Medical Center), David G. Kirsch(Princess Margaret Cancer Centre), Walter J. Urba(Providence Portland Medical Center), Zhaoyu Sun(Providence Portland Medical Center), Ziqiang Zhang(Chinese PLA General Hospital), Rutulkumar Patel(Duke Medical Center), R. Bryan Bell(Takara (United States)), Warren Floyd(Duke Medical Center), Venkatesh Rajamanickam(Cancer Institute (WIA)), John Welle(Providence Health & Services), Brady Bernard(Providence Portland Medical Center), Brian Piening(Providence College), Eric S. Xu(Duke Medical Center), So Young Kim(Chungbuk National University), Yan Ma(Duke Medical Center), Lixia Luo(Hunan University), Xingliang Liu(Sun Yat-sen University), Yaping Wu(Shanghai Jiao Tong University), Wesley Rosales(Providence Portland Medical Center), Melissa J. Kasiewicz(Providence Portland Medical Center), William Haugh(Providence Portland Medical Center), William L. Redmond(Providence St. Vincent Medical Center)
Cited by 0
Related Papers
Comprehensive molecular characterization of gastric adenocarcinoma
|Nature|2014|6.6k
The Somatic Genomic Landscape of Glioblastoma
|Cell|2013|5.2k
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1
|Nature|2009|4.2k
An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics
|Cell|2018|4k
Genomic Classification of Cutaneous Melanoma
|Cell|2015|3.3k